These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15764173)

  • 1. Surveillance of triazole susceptibility of colonizing yeasts in patients with haematological malignancies.
    Chryssanthou E; Cherif H; Petrini B; Kalin M; Björkholm M
    Scand J Infect Dis; 2004; 36(11-12):855-9. PubMed ID: 15764173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant Saccharomyces cerevisiae.
    Salonen JH; Richardson MD; Gallacher K; Issakainen J; Helenius H; Lehtonen OP; Nikoskelainen J
    J Hosp Infect; 2000 Aug; 45(4):293-301. PubMed ID: 10973747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing.
    Buchta V; Vejsova M; Vale-Silva LA
    Folia Microbiol (Praha); 2008; 53(2):153-60. PubMed ID: 18837162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of antifungal prophylaxis on the gastrointestinal yeast colonisation in patients with haematological malignancies].
    Rimek D; Redetzke K; Kappe R
    Mycoses; 2006; 49 Suppl 2():18-23. PubMed ID: 17022757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
    Arredondo-García JL; Amábile-Cuevas CF;
    J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole activity against clinical yeast isolates: a multicentre Italian study.
    Morace G; Polonelli L;
    Int J Antimicrob Agents; 2005 Sep; 26(3):247-53. PubMed ID: 16051469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.
    Belazi M; Velegraki A; Koussidou-Eremondi T; Andreadis D; Hini S; Arsenis G; Eliopoulou C; Destouni E; Antoniades D
    Oral Microbiol Immunol; 2004 Dec; 19(6):347-51. PubMed ID: 15491459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
    Seifert H; Aurbach U; Stefanik D; Cornely O
    Antimicrob Agents Chemother; 2007 May; 51(5):1818-21. PubMed ID: 17307977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period.
    Kucukates E; Erturan Z; Susever S; Yegenoglu Y
    APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
    Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
    J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
    Fleck R; Dietz A; Hof H
    J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
    Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
    Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility patterns of Candida species recovered from Canadian intensive care units.
    Laverdiere M; Labbé AC; Restieri C; Rotstein C; Heyland D; Madger S; Stewart T
    J Crit Care; 2007 Sep; 22(3):245-50. PubMed ID: 17869976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    Glasmacher A; Prentice AG
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility to antifungal agents of Candida species isolated from paediatric and adult patients with haematological diseases.
    Nawrot U; Nowicka J; Juszczak K; Gusin B
    Mycoses; 2005 Nov; 48(6):385-90. PubMed ID: 16262874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent synergic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry.
    Pina-Vaz C; Rodrigues AG; Costa-de-Oliveira S; Ricardo E; Mårdh PA
    J Antimicrob Chemother; 2005 Oct; 56(4):678-85. PubMed ID: 16115827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.